Noga Or-Geva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Noga Or-Geva has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Yair Reisner
Department of Immunology, Weizmann Institute of Science , Rehovot 7610001
10 shared publications Assaf Lask
Immunology Department, Weizmann Institute of Science, Rehovot, Israel
3 shared publicationsDavid Hagin
Immunology Department, Weizmann Institute of Science, Rehovot, Israel
3 shared publications- Lawrence Steinman
Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA
3 shared publications Yaki Eidelstein
Immunology Department, Weizmann Institute of Science, Rehovot, Israel
3 shared publicationsEran Ophir
Immunology Department, Weizmann Institute of Science, Rehovot, Israel
2 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1)
C1-esterase Inhibitor Treatment is Associated with Immune and Vascular Pathway Modulation in PASC with Neurological Symptoms: Longitudinal Plasma Proteomics
Post-acute sequelae of SARS-CoV-2 infection (PASC), particularly neurological manifestations, remain a significant therapeutic challenge, likely driven by persistent inflammation, immune dysregulation, and endothelial dysfunction. In a randomized, double-blind, placebo-controlled crossover trial, 10 patients with post-COVID-19 neurological symptoms received C1-esterase inhibitor (C1-INH; RUCONEST®) or placebo over two eight-week phases. Longitudinal plasma proteomics (SomaScan®) profiled molecular dynamics during and after C1-INH treatment. C1-INH administration was associated with distinct, phase-specific proteomic signatures, including lower levels of inflammatory-associated proteins such as CRP and IL-6, increased levels of neuroimmune and endothelial repair proteins (Neuropilin-2, CD83, C1QTNF5), and modulation of bradykinin-kinin and extracellular matrix pathways. These molecular shifts were evaluated in relation to clinical change scores during the active treatment windows. Several proteomic changes were observed at timepoint 26 after treatment cessation, describing candidate post-treatment molecular trajectories. In conclusion, these results provide exploratory mechanistic insights and support the need for validation in larger, prospective cohorts. Together, these findings prioritize immune and vascular pathways for further investigation in PASC and may have relevance to other post-infectious neuroimmune conditions.
- 19 May 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1)
Open AccessC1-esterase Inhibitor Treatment is Associated with Immune and Vascular Pathway Modulation in PASC with Neurological Symptoms: Longitudinal Plasma Proteomics
Post-acute sequelae of SARS-CoV-2 infection (PASC), particularly neurological manifestations, remain a significant therapeutic challenge, likely driven by persistent inflammation, immune dysregulation, and endothelial dysfunction. In a randomized, double-blind, placebo-controlled crossover trial, 10 patients with post-COVID-19 neurological symptoms received C1-esterase inhibitor (C1-INH; RUCONEST®) or placebo over two eight-week phases. Longitudinal plasma proteomics (SomaScan®) profiled molecular dynamics during and after C1-INH treatment. C1-INH administration was associated with distinct, phase-specific proteomic signatures, including lower levels of inflammatory-associated proteins such as CRP and IL-6, increased levels of neuroimmune and endothelial repair proteins (Neuropilin-2, CD83, C1QTNF5), and modulation of bradykinin-kinin and extracellular matrix pathways. These molecular shifts were evaluated in relation to clinical change scores during the active treatment windows. Several proteomic changes were observed at timepoint 26 after treatment cessation, describing candidate post-treatment molecular trajectories. In conclusion, these results provide exploratory mechanistic insights and support the need for validation in larger, prospective cohorts. Together, these findings prioritize immune and vascular pathways for further investigation in PASC and may have relevance to other post-infectious neuroimmune conditions.
- Top Cited PapersOpen Access
- 10 March 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (11)
Epstein–Barr virus and the immune microenvironment in multiple sclerosis: Insights from high-dimensional brain tissue imaging
Epstein–Barr virus (EBV) is strongly implicated in the pathogenesis of multiple sclerosis (MS), yet its exact role in disease progression remains unclear. Using high-dimensional CO-detection by indexing, a technology for spatial imaging, this study examines the cellular microenvironment of MS lesions in secondary progressive MS and primary progressive MS. We analyzed immune, glial, neuronal, and endothelial cell interactions within MS lesions and normal-appearing white matter across two independent cohorts. Our findings show the enrichment of EBV markers, particularly EBNA1 and LMP1, within MS lesions. EBV-positive cells interact closely with reactive astrocytes, microglia, and neurons. Image analysis confirmed the presence of EBV-positive staining within neurons and glial cells, suggesting a direct role for EBV in neuronal and glial involvement in MS. Additionally, we observed altered immune cell interactions, including reduced associations with macrophages and memory T cells, and enhanced interactions with glial cells. Disruptions in blood–brain barrier integrity were also noted in regions of the MS brain. These results highlight EBV’s contribution to immune modulation, glial dysfunction, and neuronal damage in MS, particularly in progressive subtypes. The analysis of MS brain tissue suggests potential therapeutic targets, including antivirals and brain penetrant immune modulators, to address EBV’s impact on MS progression.
- 10 March 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (11)
Top Cited PapersOpen AccessEpstein–Barr virus and the immune microenvironment in multiple sclerosis: Insights from high-dimensional brain tissue imaging
Epstein–Barr virus (EBV) is strongly implicated in the pathogenesis of multiple sclerosis (MS), yet its exact role in disease progression remains unclear. Using high-dimensional CO-detection by indexing, a technology for spatial imaging, this study examines the cellular microenvironment of MS lesions in secondary progressive MS and primary progressive MS. We analyzed immune, glial, neuronal, and endothelial cell interactions within MS lesions and normal-appearing white matter across two independent cohorts. Our findings show the enrichment of EBV markers, particularly EBNA1 and LMP1, within MS lesions. EBV-positive cells interact closely with reactive astrocytes, microglia, and neurons. Image analysis confirmed the presence of EBV-positive staining within neurons and glial cells, suggesting a direct role for EBV in neuronal and glial involvement in MS. Additionally, we observed altered immune cell interactions, including reduced associations with macrophages and memory T cells, and enhanced interactions with glial cells. Disruptions in blood–brain barrier integrity were also noted in regions of the MS brain. These results highlight EBV’s contribution to immune modulation, glial dysfunction, and neuronal damage in MS, particularly in progressive subtypes. The analysis of MS brain tissue suggests potential therapeutic targets, including antivirals and brain penetrant immune modulators, to address EBV’s impact on MS progression.
- 15 February 2024
- Published by Springer Nature in Nature Neuroscience
- Vol. 27 (3) , 393-394
Hunger guides immunity to friend versus foe
- 15 February 2024
- Published by Springer Nature in Nature Neuroscience
- Vol. 27 (3) , 393-394
Hunger guides immunity to friend versus foe
- 1 July 2019
- Published by Elsevier in Seminars in Hematology
- Vol. 56 (3) , 173-182
Veto cells for safer nonmyeloablative haploidentical HSCT and CAR T cell therapy
- 1 July 2019
- Published by Elsevier in Seminars in Hematology
- Vol. 56 (3) , 173-182
Veto cells for safer nonmyeloablative haploidentical HSCT and CAR T cell therapy
- Open Access
- 1 July 2018
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 5 (4) , e466
Molecular signature of Epstein-Barr virus infection in MS brain lesions
Objective We sought to confirm the presence and frequency of B cells and Epstein-Barr virus (EBV) (latent and lytic phase) antigens in archived MS and non-MS brain tissue by immunohistochemistry. Methods We quantified the type and location of B-cell subsets within active and chronic MS brain lesions in relation to viral antigen expression. The presence of EBV-infected cells was further confirmed by in situ hybridization to detect the EBV RNA transcript, EBV-encoded RNA-1 (EBER-1). Results We report the presence of EBV latent membrane protein 1 (LMP-1) in 93% of MS and 78% of control brains, with a greater percentage of MS brains containing CD138+ plasma cells and LMP-1–rich populations. Notably, 78% of chronic MS lesions and 33.3% of non-MS brains contained parenchymal CD138+ plasma cells. EBV early lytic protein, EBV immediate-early lytic gene (BZLF1), was also observed in 46% of MS, primarily in association with chronic lesions and 44% of non-MS brain tissue. Furthermore, 85% of MS brains revealed frequent EBER-positive cells, whereas non-MS brains seldom contained EBER-positive cells. EBV infection was detectable, by immunohistochemistry and by in situ hybridization, in both MS and non-MS brains, although latent virus was more prevalent in MS brains, while lytic virus was restricted to chronic MS lesions. Conclusions Together, our observations suggest an uncharacterized link between the EBV virus life cycle and MS pathogenesis.
- 1 July 2018
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 5 (4) , e466
Open AccessMolecular signature of Epstein-Barr virus infection in MS brain lesions
Objective We sought to confirm the presence and frequency of B cells and Epstein-Barr virus (EBV) (latent and lytic phase) antigens in archived MS and non-MS brain tissue by immunohistochemistry. Methods We quantified the type and location of B-cell subsets within active and chronic MS brain lesions in relation to viral antigen expression. The presence of EBV-infected cells was further confirmed by in situ hybridization to detect the EBV RNA transcript, EBV-encoded RNA-1 (EBER-1). Results We report the presence of EBV latent membrane protein 1 (LMP-1) in 93% of MS and 78% of control brains, with a greater percentage of MS brains containing CD138+ plasma cells and LMP-1–rich populations. Notably, 78% of chronic MS lesions and 33.3% of non-MS brains contained parenchymal CD138+ plasma cells. EBV early lytic protein, EBV immediate-early lytic gene (BZLF1), was also observed in 46% of MS, primarily in association with chronic lesions and 44% of non-MS brain tissue. Furthermore, 85% of MS brains revealed frequent EBER-positive cells, whereas non-MS brains seldom contained EBER-positive cells. EBV infection was detectable, by immunohistochemistry and by in situ hybridization, in both MS and non-MS brains, although latent virus was more prevalent in MS brains, while lytic virus was restricted to chronic MS lesions. Conclusions Together, our observations suggest an uncharacterized link between the EBV virus life cycle and MS pathogenesis.
- 20 November 2017
- Published by Springer Nature in Leukemia
- Vol. 32 (4) , 1038-1040
Towards ‘off-the-shelf’ genetically modified T cells: prolonging functional engraftment in mice by CD8 veto T cells
- 20 November 2017
- Published by Springer Nature in Leukemia
- Vol. 32 (4) , 1038-1040
Towards ‘off-the-shelf’ genetically modified T cells: prolonging functional engraftment in mice by CD8 veto T cells
- Open Access
- 30 October 2017
- Published by American Society of Hematology in Blood Advances
- Vol. 1 (24) , 2166-2175
Immune tolerance induction by nonmyeloablative haploidentical HSCT combining T-cell depletion and posttransplant cyclophosphamide
Key Points: This study lays the foundation for the use of nonmyeloablative GVHD-free haploidentical HSCT. This approach offers treatment of hematological diseases and a safe potential platform for cell therapy and organ transplantation.
- 30 October 2017
- Published by American Society of Hematology in Blood Advances
- Vol. 1 (24) , 2166-2175
Open AccessImmune tolerance induction by nonmyeloablative haploidentical HSCT combining T-cell depletion and posttransplant cyclophosphamide
Key Points: This study lays the foundation for the use of nonmyeloablative GVHD-free haploidentical HSCT. This approach offers treatment of hematological diseases and a safe potential platform for cell therapy and organ transplantation.
- 18 December 2015
- Published by Wiley in British Journal of Haematology
- Vol. 172 (5) , 667-684
The evolution of T‐cell depletion in haploidentical stem‐cell transplantation
Summary: T‐cell depletion (TCD) can prevent the onset of graft‐versus‐host disease (GvHD) in animal models of bone marrow transplantation; this manipulation enabled the successful application in the 1980s of T‐cell depleted bone marrow (BM) for the treatment of babies with severe combined immune deficiency (SCID). However, in leukaemia patients, implementation of T‐cell depletion has been more difficult, especially due to high rate of graft‐rejection, leukaemia relapse and delayed immune reconstitution. These hurdles were gradually overcome by modifying the cell composition of the graft, and by reducing the toxicities associated with conditioning protocols. Although no ‘gold standard’ TCD method exists, T‐cell depletion in its modern forms could offer clinical benefit, even for patients with a matched sibling donor.
- 18 December 2015
- Published by Wiley in British Journal of Haematology
- Vol. 172 (5) , 667-684
The evolution of T‐cell depletion in haploidentical stem‐cell transplantation
Summary: T‐cell depletion (TCD) can prevent the onset of graft‐versus‐host disease (GvHD) in animal models of bone marrow transplantation; this manipulation enabled the successful application in the 1980s of T‐cell depleted bone marrow (BM) for the treatment of babies with severe combined immune deficiency (SCID). However, in leukaemia patients, implementation of T‐cell depletion has been more difficult, especially due to high rate of graft‐rejection, leukaemia relapse and delayed immune reconstitution. These hurdles were gradually overcome by modifying the cell composition of the graft, and by reducing the toxicities associated with conditioning protocols. Although no ‘gold standard’ TCD method exists, T‐cell depletion in its modern forms could offer clinical benefit, even for patients with a matched sibling donor.
- 3 June 2015
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 50 (S2) , S14-S20
The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT
Allogeneic HSCT offers a route for achieving immune tolerance via mixed chimerism and remains the sole curative option for many nonmalignant, autoimmune and metabolic diseases. Present-day improvements of nonmyeloablative protocols are increasing the safety of HSCT, thereby widening the target population and resurrecting the interest of HSCT application as a platform for tolerance induction in organ transplantation. Using high cell doses of T-cell-depleted (TCD) grafts has been shown to circumvent graft-vs-host disease, leaving graft rejection as the main hindrance due to the robust host immunity that remains after mild conditioning. In this review we highlight the advantages of utilizing unique non-alloreactive 'veto' cells, such as anti-third party central memory CD8 T cells (Tcm), to enable induction of mixed chimerism after megadose HSCT under nonmyeloablative conditioning. Co-administration of HSCT with veto Tcm allows for induction of mixed chimerism that was successfully translated into immune tolerance, as demonstrated by engraftment of donor-type skin grafts. These veto Tcm cells have been shown to specifically eradicate anti-donor host T cells, through lymph-node sequestration and deletion, thus sparing host immunity and circumventing the need for life-long immunosuppression. Hence, data indicate that this treatment modality of combined TCD HSCT and adoptive transfer of Tcm veto cells under nonmyeloablative conditions may serve as a valuable tool for treatment of patients with a wide array of disorders such as hemoglobinopathies, autoimmune diseases and as a prelude for organ tolerance.
- 3 June 2015
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 50 (S2) , S14-S20
The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT
Allogeneic HSCT offers a route for achieving immune tolerance via mixed chimerism and remains the sole curative option for many nonmalignant, autoimmune and metabolic diseases. Present-day improvements of nonmyeloablative protocols are increasing the safety of HSCT, thereby widening the target population and resurrecting the interest of HSCT application as a platform for tolerance induction in organ transplantation. Using high cell doses of T-cell-depleted (TCD) grafts has been shown to circumvent graft-vs-host disease, leaving graft rejection as the main hindrance due to the robust host immunity that remains after mild conditioning. In this review we highlight the advantages of utilizing unique non-alloreactive 'veto' cells, such as anti-third party central memory CD8 T cells (Tcm), to enable induction of mixed chimerism after megadose HSCT under nonmyeloablative conditioning. Co-administration of HSCT with veto Tcm allows for induction of mixed chimerism that was successfully translated into immune tolerance, as demonstrated by engraftment of donor-type skin grafts. These veto Tcm cells have been shown to specifically eradicate anti-donor host T cells, through lymph-node sequestration and deletion, thus sparing host immunity and circumventing the need for life-long immunosuppression. Hence, data indicate that this treatment modality of combined TCD HSCT and adoptive transfer of Tcm veto cells under nonmyeloablative conditions may serve as a valuable tool for treatment of patients with a wide array of disorders such as hemoglobinopathies, autoimmune diseases and as a prelude for organ tolerance.
- 1 May 2015
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 10 (3) , 239-242
Exercising ‘Veto’ Power to Make Haploidentical Hematopoietic Stem Cell Transplantation a Safe Modality for Induction of Immune Tolerance
- 1 May 2015
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 10 (3) , 239-242
Exercising ‘Veto’ Power to Make Haploidentical Hematopoietic Stem Cell Transplantation a Safe Modality for Induction of Immune Tolerance